diff --git "a/dev_JRCT_api/vector_searchE1.ipynb" "b/dev_JRCT_api/vector_searchE1.ipynb"
new file mode 100644--- /dev/null
+++ "b/dev_JRCT_api/vector_searchE1.ipynb"
@@ -0,0 +1,2050 @@
+{
+ "cells": [
+  {
+   "cell_type": "code",
+   "execution_count": 1,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stderr",
+     "output_type": "stream",
+     "text": [
+      "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:13: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n",
+      "  from tqdm.autonotebook import tqdm, trange\n"
+     ]
+    }
+   ],
+   "source": [
+    "from sentence_transformers import SentenceTransformer, util\n",
+    "import pandas as pd\n",
+    "import re"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 14,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Target列を分割する関数\n",
+    "def split_target(target):\n",
+    "    # 指定された区切り文字で分割\n",
+    "    split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n",
+    "    # 空白文字を除外してリストとして返す\n",
+    "    return [word.strip() for word in split_words if word.strip()]\n",
+    "\n",
+    "\n",
+    "# Target列を分割する関数（改良後）\n",
+    "def split_target_English(target):\n",
+    "    # 区切り文字を (,) or (\\n) or (、) or (・) または文字列\"or\" として扱う\n",
+    "    # 正規表現では、パイプ(|)でor条件を定義し、\"(?: ... )\"はグルーピングのみ行う非捕捉グループ\n",
+    "    # [,\\n、・] はいずれかの1文字とマッチ\n",
+    "    # or は文字列全体とマッチ\n",
+    "    # 複数連続した区切り文字をまとめて1回の分割として扱うために+(1回以上)とする\n",
+    "    split_words = re.split(r'(?:[,\\n、・]|or)+', target)\n",
+    "    \n",
+    "    # 空白文字を除外してリストとして返す\n",
+    "    return [word.strip() for word in split_words if word.strip()]"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 15,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241215Cancer.csv', index_col=0)\n",
+    "basedf = basedf.dropna(subset=['試験等のフェーズ'])\n",
+    "# Target列を分割してTargetWord列を追加\n",
+    "basedf['TargetWord'] = basedf['TargetEnglish'].apply(split_target_English)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 16,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>JRCT ID</th>\n",
+       "      <th>NCT No</th>\n",
+       "      <th>JapicCTI No</th>\n",
+       "      <th>Title</th>\n",
+       "      <th>TargetJ</th>\n",
+       "      <th>Target</th>\n",
+       "      <th>TargetEnglish</th>\n",
+       "      <th>研究・治験の目的</th>\n",
+       "      <th>試験等のフェーズ</th>\n",
+       "      <th>試験の種類</th>\n",
+       "      <th>...</th>\n",
+       "      <th>purpose</th>\n",
+       "      <th>Inclusion Criteria</th>\n",
+       "      <th>Exclusion Criteria</th>\n",
+       "      <th>Age Minimum</th>\n",
+       "      <th>Age Maximum</th>\n",
+       "      <th>Gender</th>\n",
+       "      <th>Discontinuation Criteria</th>\n",
+       "      <th>Keyword</th>\n",
+       "      <th>Intervention(s)</th>\n",
+       "      <th>TargetWord</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>jRCT2031240552</td>\n",
+       "      <td>NCT06599502</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>KRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併...</td>\n",
+       "      <td>以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌</td>\n",
+       "      <td>以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌</td>\n",
+       "      <td>Non-Small Cell Lung Cancer (NSCLC) Pancreatic ...</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Participant must be 18 years or more, or th...</td>\n",
+       "      <td>1. Any significant laboratory finding or any s...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>AZD0022</td>\n",
+       "      <td>[Non-Small Cell Lung Cancer (NSCLC) Pancreatic...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3</th>\n",
+       "      <td>jRCT2031240547</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>FGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu...</td>\n",
+       "      <td>切除不能進行・再発の胃または食道胃接合部腺癌</td>\n",
+       "      <td>切除不能進行・再発の胃または食道胃接合部腺癌</td>\n",
+       "      <td>Advanced Gastric or Gastroesophageal Junction ...</td>\n",
+       "      <td>フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1) Histologically documented gastric or GEJ ad...</td>\n",
+       "      <td>1) Prior treatment with taxanes 2) Prior treat...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>- Bemarituzumab (15mg/kg, intravenous, Day1, 1...</td>\n",
+       "      <td>[Advanced Gastric, Gastroesophageal Junction C...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>5</th>\n",
+       "      <td>jRCT2031240542</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド...</td>\n",
+       "      <td>多発性骨髄腫</td>\n",
+       "      <td>多発性骨髄腫</td>\n",
+       "      <td>Multiple Myeloma</td>\n",
+       "      <td>自家造血幹細胞移植非適応の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Is at least 18 or the legal age of consent ...</td>\n",
+       "      <td>Participants are excluded from the study if an...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm A: Belantamab Mafodotin is intraveniously ...</td>\n",
+       "      <td>[Multiple Myeloma]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>7</th>\n",
+       "      <td>jRCT2031240536</td>\n",
+       "      <td>NCT06003231</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita...</td>\n",
+       "      <td>頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌</td>\n",
+       "      <td>頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌</td>\n",
+       "      <td>Head and neck squamous cell carcinoma/Non-smal...</td>\n",
+       "      <td>既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Cohort 1: Head and neck squamous cell carcinom...</td>\n",
+       "      <td>- Prior treatment with a monomethyl auristatin...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Experimental Arm - Disitamab vedotin 1.5 mg/kg...</td>\n",
+       "      <td>[Head and neck squamous cell carcinoma/Non-sma...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>9</th>\n",
+       "      <td>jRCT2031240530</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra...</td>\n",
+       "      <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...</td>\n",
+       "      <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...</td>\n",
+       "      <td>Stage II-III HER2-Amplified or HER2-Mutant Non...</td>\n",
+       "      <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Signed informed consent form 2. Age &gt;= 18 y...</td>\n",
+       "      <td>1. NSCLC that is clinically T4 by virtue of me...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>The study drug will be administered as an IV i...</td>\n",
+       "      <td>[Stage II-III HER2-Amplified, HER2-Mutant Non-...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>...</th>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>729</th>\n",
+       "      <td>jRCT2031200057</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>&lt;Disease Characteristics&gt; 1)Patients with inop...</td>\n",
+       "      <td>1)Patients correspond to either of the followi...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>For the target tumor, the dose settled at each...</td>\n",
+       "      <td>[Breast cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>739</th>\n",
+       "      <td>jRCT2073200004</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験</td>\n",
+       "      <td>膵癌</td>\n",
+       "      <td>膵癌</td>\n",
+       "      <td>Pancreatic cancer</td>\n",
+       "      <td>切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>The patients with pancreatic tumors must meet ...</td>\n",
+       "      <td>1) Patients with the following complications: ...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Pancreatic ductal carcinoma, unresectable</td>\n",
+       "      <td>Intratumoral administration of oncolytic virus</td>\n",
+       "      <td>[Pancreatic cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>760</th>\n",
+       "      <td>jRCT2033190086</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...</td>\n",
+       "      <td>悪性黒色腫</td>\n",
+       "      <td>悪性黒色腫</td>\n",
+       "      <td>malignant melanoma</td>\n",
+       "      <td>第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(Phase 1) 1) Histologically confirmed malignan...</td>\n",
+       "      <td>(Phase 1 and 2) 1) Patients who have brain and...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>malignamt melanoma, advanced stage</td>\n",
+       "      <td>Test drug (T-hIL12) will be administered into ...</td>\n",
+       "      <td>[malignant melanoma]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>762</th>\n",
+       "      <td>jRCT2031190072</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験</td>\n",
+       "      <td>肝細胞癌</td>\n",
+       "      <td>肝細胞癌</td>\n",
+       "      <td>Hepatocellular carcinoma</td>\n",
+       "      <td>切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1) Histologically or cytologically confirmed h...</td>\n",
+       "      <td>1) CNS metastases that are symptomatic or requ...</td>\n",
+       "      <td>20age 0month 0week old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Cancer peptide vaccine</td>\n",
+       "      <td>Reconstitute two kinds of cancer peptide vacci...</td>\n",
+       "      <td>[Hepatocellular carcinoma]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>772</th>\n",
+       "      <td>jRCT2051190009</td>\n",
+       "      <td>NCT03818893</td>\n",
+       "      <td>JapicCTI-194618</td>\n",
+       "      <td>進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...</td>\n",
+       "      <td>進行性悪性黒色腫</td>\n",
+       "      <td>進行性悪性黒色腫</td>\n",
+       "      <td>advanced melanoma</td>\n",
+       "      <td>抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Inclusion criteria Patients meeting all of the...</td>\n",
+       "      <td>Exclusion criteria Patients meeting any of the...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>86age old not</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>advanced melanoma</td>\n",
+       "      <td>combination therapy of intracutaneous GEN0101 ...</td>\n",
+       "      <td>[advanced melanoma]</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>427 rows × 40 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "            JRCT ID       NCT No      JapicCTI No  \\\n",
+       "0    jRCT2031240552  NCT06599502              NaN   \n",
+       "3    jRCT2031240547          NaN              NaN   \n",
+       "5    jRCT2031240542          NaN              NaN   \n",
+       "7    jRCT2031240536  NCT06003231              NaN   \n",
+       "9    jRCT2031240530          NaN              NaN   \n",
+       "..              ...          ...              ...   \n",
+       "729  jRCT2031200057          NaN              NaN   \n",
+       "739  jRCT2073200004          NaN              NaN   \n",
+       "760  jRCT2033190086          NaN              NaN   \n",
+       "762  jRCT2031190072          NaN              NaN   \n",
+       "772  jRCT2051190009  NCT03818893  JapicCTI-194618   \n",
+       "\n",
+       "                                                 Title  \\\n",
+       "0    KRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併...   \n",
+       "3    FGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu...   \n",
+       "5    自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド...   \n",
+       "7    既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita...   \n",
+       "9    HER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra...   \n",
+       "..                                                 ...   \n",
+       "729      治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験   \n",
+       "739            切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験   \n",
+       "760  悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...   \n",
+       "762                  切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験   \n",
+       "772  進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...   \n",
+       "\n",
+       "                                               TargetJ  \\\n",
+       "0                 以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌   \n",
+       "3                               切除不能進行・再発の胃または食道胃接合部腺癌   \n",
+       "5                                               多発性骨髄腫   \n",
+       "7                            頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌   \n",
+       "9    HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...   \n",
+       "..                                                 ...   \n",
+       "729                                                乳がん   \n",
+       "739                                                 膵癌   \n",
+       "760                                              悪性黒色腫   \n",
+       "762                                               肝細胞癌   \n",
+       "772                                           進行性悪性黒色腫   \n",
+       "\n",
+       "                                                Target  \\\n",
+       "0                    以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌   \n",
+       "3                               切除不能進行・再発の胃または食道胃接合部腺癌   \n",
+       "5                                               多発性骨髄腫   \n",
+       "7                            頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌   \n",
+       "9    HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...   \n",
+       "..                                                 ...   \n",
+       "729                                                乳がん   \n",
+       "739                                                 膵癌   \n",
+       "760                                              悪性黒色腫   \n",
+       "762                                               肝細胞癌   \n",
+       "772                                           進行性悪性黒色腫   \n",
+       "\n",
+       "                                         TargetEnglish  \\\n",
+       "0    Non-Small Cell Lung Cancer (NSCLC) Pancreatic ...   \n",
+       "3    Advanced Gastric or Gastroesophageal Junction ...   \n",
+       "5                                     Multiple Myeloma   \n",
+       "7    Head and neck squamous cell carcinoma/Non-smal...   \n",
+       "9    Stage II-III HER2-Amplified or HER2-Mutant Non...   \n",
+       "..                                                 ...   \n",
+       "729                                      Breast cancer   \n",
+       "739                                  Pancreatic cancer   \n",
+       "760                                 malignant melanoma   \n",
+       "762                           Hepatocellular carcinoma   \n",
+       "772                                  advanced melanoma   \n",
+       "\n",
+       "                                              研究・治験の目的 試験等のフェーズ 試験の種類  ...  \\\n",
+       "0                                            Treatment      1-2   NaN  ...   \n",
+       "3    フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又...        2   NaN  ...   \n",
+       "5    自家造血幹細胞移植非適応の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ...        3   NaN  ...   \n",
+       "7    既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形...        2   NaN  ...   \n",
+       "9    HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...        2   NaN  ...   \n",
+       "..                                                 ...      ...   ...  ...   \n",
+       "729  TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...        1   NaN  ...   \n",
+       "739      切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。      1-2   NaN  ...   \n",
+       "760  第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...      1-2   NaN  ...   \n",
+       "762                  切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験        1   NaN  ...   \n",
+       "772  抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...      1-2   NaN  ...   \n",
+       "\n",
+       "               purpose                                 Inclusion Criteria  \\\n",
+       "0    treatment purpose  1. Participant must be 18 years or more, or th...   \n",
+       "3    treatment purpose  1) Histologically documented gastric or GEJ ad...   \n",
+       "5    treatment purpose  1. Is at least 18 or the legal age of consent ...   \n",
+       "7    treatment purpose  Cohort 1: Head and neck squamous cell carcinom...   \n",
+       "9    treatment purpose  1. Signed informed consent form 2. Age >= 18 y...   \n",
+       "..                 ...                                                ...   \n",
+       "729  treatment purpose  <Disease Characteristics> 1)Patients with inop...   \n",
+       "739  treatment purpose  The patients with pancreatic tumors must meet ...   \n",
+       "760  treatment purpose  (Phase 1) 1) Histologically confirmed malignan...   \n",
+       "762  treatment purpose  1) Histologically or cytologically confirmed h...   \n",
+       "772  treatment purpose  Inclusion criteria Patients meeting all of the...   \n",
+       "\n",
+       "                                    Exclusion Criteria  \\\n",
+       "0    1. Any significant laboratory finding or any s...   \n",
+       "3    1) Prior treatment with taxanes 2) Prior treat...   \n",
+       "5    Participants are excluded from the study if an...   \n",
+       "7    - Prior treatment with a monomethyl auristatin...   \n",
+       "9    1. NSCLC that is clinically T4 by virtue of me...   \n",
+       "..                                                 ...   \n",
+       "729  1)Patients correspond to either of the followi...   \n",
+       "739  1) Patients with the following complications: ...   \n",
+       "760  (Phase 1 and 2) 1) Patients who have brain and...   \n",
+       "762  1) CNS metastases that are symptomatic or requ...   \n",
+       "772  Exclusion criteria Patients meeting any of the...   \n",
+       "\n",
+       "                     Age Minimum    Age Maximum  Gender  \\\n",
+       "0                 18age old over       No limit    Both   \n",
+       "3                 18age old over       No limit    Both   \n",
+       "5                 18age old over       No limit    Both   \n",
+       "7                 18age old over       No limit    Both   \n",
+       "9                 18age old over       No limit    Both   \n",
+       "..                           ...            ...     ...   \n",
+       "729               20age old over       No limit  Female   \n",
+       "739               20age old over       No limit    Both   \n",
+       "760               20age old over       No limit    Both   \n",
+       "762  20age 0month 0week old over       No limit    Both   \n",
+       "772               20age old over  86age old not    Both   \n",
+       "\n",
+       "    Discontinuation Criteria                                    Keyword  \\\n",
+       "0                        NaN                                        NaN   \n",
+       "3                        NaN                                        NaN   \n",
+       "5                        NaN                                        NaN   \n",
+       "7                        NaN                                        NaN   \n",
+       "9                        NaN                                        NaN   \n",
+       "..                       ...                                        ...   \n",
+       "729                      NaN                              Breast cancer   \n",
+       "739                      NaN  Pancreatic ductal carcinoma, unresectable   \n",
+       "760                      NaN         malignamt melanoma, advanced stage   \n",
+       "762                      NaN                     Cancer peptide vaccine   \n",
+       "772                      NaN                          advanced melanoma   \n",
+       "\n",
+       "                                       Intervention(s)  \\\n",
+       "0                                              AZD0022   \n",
+       "3    - Bemarituzumab (15mg/kg, intravenous, Day1, 1...   \n",
+       "5    Arm A: Belantamab Mafodotin is intraveniously ...   \n",
+       "7    Experimental Arm - Disitamab vedotin 1.5 mg/kg...   \n",
+       "9    The study drug will be administered as an IV i...   \n",
+       "..                                                 ...   \n",
+       "729  For the target tumor, the dose settled at each...   \n",
+       "739     Intratumoral administration of oncolytic virus   \n",
+       "760  Test drug (T-hIL12) will be administered into ...   \n",
+       "762  Reconstitute two kinds of cancer peptide vacci...   \n",
+       "772  combination therapy of intracutaneous GEN0101 ...   \n",
+       "\n",
+       "                                            TargetWord  \n",
+       "0    [Non-Small Cell Lung Cancer (NSCLC) Pancreatic...  \n",
+       "3    [Advanced Gastric, Gastroesophageal Junction C...  \n",
+       "5                                   [Multiple Myeloma]  \n",
+       "7    [Head and neck squamous cell carcinoma/Non-sma...  \n",
+       "9    [Stage II-III HER2-Amplified, HER2-Mutant Non-...  \n",
+       "..                                                 ...  \n",
+       "729                                    [Breast cancer]  \n",
+       "739                                [Pancreatic cancer]  \n",
+       "760                               [malignant melanoma]  \n",
+       "762                         [Hepatocellular carcinoma]  \n",
+       "772                                [advanced melanoma]  \n",
+       "\n",
+       "[427 rows x 40 columns]"
+      ]
+     },
+     "execution_count": 16,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "basedf.dropna(subset=['TargetEnglish'])"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 17,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "67f75d0e635b41a488f77601d930e4d1",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "modules.json:   0%|          | 0.00/349 [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    },
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "1551a047d06c4c0887b8d6331389f475",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "config_sentence_transformers.json:   0%|          | 0.00/116 [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    },
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "8bb034be14554f05806e284e3978de5b",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "README.md:   0%|          | 0.00/10.6k [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    },
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "af1bf85af4e3424890881646a70db423",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "sentence_bert_config.json:   0%|          | 0.00/53.0 [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    },
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "a6c9c8577d0d44caa247b6c2ae60832a",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "config.json:   0%|          | 0.00/571 [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    },
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "db75a9d07771411d81d66195a4e1563c",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "model.safetensors:   0%|          | 0.00/438M [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    },
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "9c9cd9ebe0a04a5f8d57120405a97248",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "tokenizer_config.json:   0%|          | 0.00/363 [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    },
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "79c9feca90f14b6f88d9a1c175a74f8f",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "vocab.txt:   0%|          | 0.00/232k [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    },
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "26f5d87067cc4f3083c33b72e56a27a7",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "tokenizer.json:   0%|          | 0.00/466k [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    },
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "9a465b62659d41c3aa324d2e03902b51",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "special_tokens_map.json:   0%|          | 0.00/239 [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    },
+    {
+     "name": "stderr",
+     "output_type": "stream",
+     "text": [
+      "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
+      "  warnings.warn(\n"
+     ]
+    },
+    {
+     "data": {
+      "application/vnd.jupyter.widget-view+json": {
+       "model_id": "25ed39dfce054cbc9306c3bea9ab1963",
+       "version_major": 2,
+       "version_minor": 0
+      },
+      "text/plain": [
+       "1_Pooling/config.json:   0%|          | 0.00/190 [00:00<?, ?B/s]"
+      ]
+     },
+     "metadata": {},
+     "output_type": "display_data"
+    }
+   ],
+   "source": [
+    "# モデルのロード\n",
+    "model = SentenceTransformer('all-mpnet-base-v2')"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 52,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# クエリ\n",
+    "query = \"Triple negative breast cancer\"\n",
+    "query = \"breast cancer\"\n",
+    "#query = \"glioma\"\n",
+    "threshold = 0.7\n",
+    "# クエリをベクトル化\n",
+    "query_vec = model.encode(query, convert_to_tensor=True)\n"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 53,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>JRCT ID</th>\n",
+       "      <th>NCT No</th>\n",
+       "      <th>JapicCTI No</th>\n",
+       "      <th>Title</th>\n",
+       "      <th>TargetJ</th>\n",
+       "      <th>Target</th>\n",
+       "      <th>TargetEnglish</th>\n",
+       "      <th>研究・治験の目的</th>\n",
+       "      <th>試験等のフェーズ</th>\n",
+       "      <th>試験の種類</th>\n",
+       "      <th>...</th>\n",
+       "      <th>purpose</th>\n",
+       "      <th>Inclusion Criteria</th>\n",
+       "      <th>Exclusion Criteria</th>\n",
+       "      <th>Age Minimum</th>\n",
+       "      <th>Age Maximum</th>\n",
+       "      <th>Gender</th>\n",
+       "      <th>Discontinuation Criteria</th>\n",
+       "      <th>Keyword</th>\n",
+       "      <th>Intervention(s)</th>\n",
+       "      <th>TargetWord</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>32</th>\n",
+       "      <td>jRCT2031240476</td>\n",
+       "      <td>NCT06312176</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>ホルモン受容体陽性・ヒト上皮成長因子受容体2陰性（HR+/HER2-）の切除不能な局所進行又...</td>\n",
+       "      <td>HR+/HER2-の切除不能局所進行又は転移性乳癌の患者</td>\n",
+       "      <td>HR+/HER2-の切除不能局所進行又は転移性乳癌の患者</td>\n",
+       "      <td>HR+/HER2 unresectable locally advanced or meta...</td>\n",
+       "      <td>HR+/HER2-の切除不能な局所進行又は転移性乳癌患者を対象にMK-2870の単剤及びペム...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Has unresectable locally advanced or metastat...</td>\n",
+       "      <td>-Has breast cancer amenable to treatment with ...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm A:MK-2870 Participants receive 4 mg/kg of ...</td>\n",
+       "      <td>[HR+/HER2 unresectable locally advanced, metas...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>112</th>\n",
+       "      <td>jRCT2031240238</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>ネクチン-4発現に関連する進行性悪性腫瘍を有する日本人患者を対象にBT8009の安全性、薬物...</td>\n",
+       "      <td>進行固形癌</td>\n",
+       "      <td>進行固形癌</td>\n",
+       "      <td>Advanced solid tumor malignancies</td>\n",
+       "      <td>第II/III相試験(NCT06225596)で使用予定のBT8009の用量について、単剤療...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Eastern Cooperative Oncology Group (ECOG) o...</td>\n",
+       "      <td>1. Current treatment with strong inhibitors or...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>In Part A, (BT8009 monotherapy) participants w...</td>\n",
+       "      <td>[Advanced solid tum, malignancies]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>157</th>\n",
+       "      <td>jRCT2052240059</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>diagnostic purpose</td>\n",
+       "      <td>1. Histologically confirmed invasive breast ca...</td>\n",
+       "      <td>1. History of other malignancy within the last...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Omitting breast surgery after preoperative che...</td>\n",
+       "      <td>[Breast cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>170</th>\n",
+       "      <td>jRCT2031240096</td>\n",
+       "      <td>NCT06380751</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...</td>\n",
+       "      <td>進行乳癌</td>\n",
+       "      <td>進行乳癌</td>\n",
+       "      <td>Advanced Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Adult females, pre/peri-menopausal and/or po...</td>\n",
+       "      <td>- Participants with history of MDS/AML or with...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Experimental: Arm 1: saruparib (AZD5305) plus ...</td>\n",
+       "      <td>[Advanced Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>209</th>\n",
+       "      <td>jRCT2031230750</td>\n",
+       "      <td>NCT06188559</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>治療歴のある HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌の被験者を対象に，...</td>\n",
+       "      <td>HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌</td>\n",
+       "      <td>HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌</td>\n",
+       "      <td>HER2-positive or HER2-low unresectable or meta...</td>\n",
+       "      <td>治療</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(1) Male or female, aged &gt;=18 years at the tim...</td>\n",
+       "      <td>(1) Presence of brain or subdural metastases, ...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Generic Name:NA Study Treatment in dose optimi...</td>\n",
+       "      <td>[HER2-positive, HER2-low unresectable, metasta...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>215</th>\n",
+       "      <td>jRCT2031230723</td>\n",
+       "      <td>NCT06112379</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Participant must be &gt;= 18 years at the time...</td>\n",
+       "      <td>1. As judged by the investigator, any evidence...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>- Experimental arm: Dato-DXd plus durvalumab n...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>224</th>\n",
+       "      <td>jRCT2051230196</td>\n",
+       "      <td>NCT06105632</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>CDK4/6 阻害薬による前治療で進行したホルモン受容体陽性HER2 陰性の進行または転移乳...</td>\n",
+       "      <td>ホルモン受容体（HR）陽性ヒト上皮増殖因子受容体2（HER2）陰性の進行または転移乳癌</td>\n",
+       "      <td>ホルモン受容体(HR)陽性ヒト上皮増殖因子受容体2(HER2)陰性の進行または転移乳癌</td>\n",
+       "      <td>HR-positive, HER2-negative Advanced or Metasta...</td>\n",
+       "      <td>CDK4/6阻害薬による前治療で進行したHR陽性HER2陰性の進行または転移乳癌患者を対象に...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>* Histological confirmation of breast cancer w...</td>\n",
+       "      <td>* Any medical or psychiatric condition that ma...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm A (Experimental Arm) PF-07220060 plus Fulv...</td>\n",
+       "      <td>[HR-positive, HER2-negative Advanced, Metastat...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>234</th>\n",
+       "      <td>jRCT2031230677</td>\n",
+       "      <td>NCT06206837</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>18歳以上のER陽性／HER2陰性の進行または転移乳癌患者を対象として，経口タンパク質分解誘...</td>\n",
+       "      <td>エストロゲン受容体陽性／ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌</td>\n",
+       "      <td>エストロゲン受容体陽性/ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌</td>\n",
+       "      <td>ER+/HER2- advanced or metastatic breast cancer</td>\n",
+       "      <td>進行乳癌患者を対象として,vepdegestrantとPF-07220060を併用投与したと...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Inclusion Criteria: * Histological or cytologi...</td>\n",
+       "      <td>Exclusion Criteria: * visceral crisis at risk ...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Drug: vepdegestrant Daily oral dosages of vepd...</td>\n",
+       "      <td>[ER+/HER2- advanced, metastatic breast cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>240</th>\n",
+       "      <td>jRCT2061230102</td>\n",
+       "      <td>NCT06103864</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Histologically or cytologically documented loc...</td>\n",
+       "      <td>As judged by investigator, severe or uncontrol...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>307</th>\n",
+       "      <td>jRCT2061230074</td>\n",
+       "      <td>NCT05952557</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>Breast Cancer, Early Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Women and Men; 18 years or more at the time ...</td>\n",
+       "      <td>- Inoperable locally advanced or metastatic br...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>arm A: continue with SoC ET as directed by inv...</td>\n",
+       "      <td>[Breast Cancer, Early Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>351</th>\n",
+       "      <td>jRCT2031230279</td>\n",
+       "      <td>NCT05862285</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...</td>\n",
+       "      <td>癌</td>\n",
+       "      <td>癌</td>\n",
+       "      <td>Cancer</td>\n",
+       "      <td>本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Eligible for continuing Roche IMP-based ther...</td>\n",
+       "      <td>- Meet any of the study treatment discontinuat...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Ipatasertib: Ipatasertib will be administered ...</td>\n",
+       "      <td>[Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>392</th>\n",
+       "      <td>jRCT2031230096</td>\n",
+       "      <td>NCT05774951</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>Breast Cancer, Early Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Women and Men, greater than or equal to 18 y...</td>\n",
+       "      <td>- Inoperable locally advanced or metastatic br...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>arm A: continue with SoC ET as directed by inv...</td>\n",
+       "      <td>[Breast Cancer, Early Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>463</th>\n",
+       "      <td>jRCT2061220087</td>\n",
+       "      <td>NCT05629585</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Participant must be &gt;= 18 years at the time of...</td>\n",
+       "      <td>Stage IV (metastatic) TNBC. History of prior i...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>130age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>515</th>\n",
+       "      <td>jRCT2031220276</td>\n",
+       "      <td>NCT05307705</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Have advanced breast cancer or another solid ...</td>\n",
+       "      <td>-Medical Conditions -Colorectal cancer -Endome...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>555</th>\n",
+       "      <td>jRCT2031220034</td>\n",
+       "      <td>NCT04862663</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>局所進行（切除不能）又は転移性のホルモン受容体陽性／ヒト上皮細胞成長因子受容体2 陰性乳癌を...</td>\n",
+       "      <td>局所進行（切除不能）又は転移性乳癌</td>\n",
+       "      <td>局所進行(切除不能)又は転移性乳癌</td>\n",
+       "      <td>Locally Advanced (Inoperable) or Metastatic Br...</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Key inclusion criteria for both phases: 1. Adu...</td>\n",
+       "      <td>Key exclusion criteria for both phases: 1. His...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>99age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Capivasertib: PO BD 4 days on /3 days off per ...</td>\n",
+       "      <td>[Locally Advanced (Inoperable), Metastatic Bre...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>590</th>\n",
+       "      <td>jRCT2031210585</td>\n",
+       "      <td>NCT05123482</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...</td>\n",
+       "      <td>乳癌、胆道癌、卵巣癌、子宮内膜癌</td>\n",
+       "      <td>乳癌、胆道癌、卵巣癌、子宮内膜癌</td>\n",
+       "      <td>Breast Cancer, Biliary Tract Carcinoma, Ovaria...</td>\n",
+       "      <td>進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Age18 years or more - Relapsed/metastatic so...</td>\n",
+       "      <td>- Treatment with any of the following: 1. Nitr...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Sub-study1 AZD8205 Monotherapy AZD8205 is an a...</td>\n",
+       "      <td>[Breast Cancer, Biliary Tract Carcinoma, Ovari...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>593</th>\n",
+       "      <td>jRCT2031210560</td>\n",
+       "      <td>NCT05061823</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...</td>\n",
+       "      <td>固形癌</td>\n",
+       "      <td>固形癌</td>\n",
+       "      <td>Cancer</td>\n",
+       "      <td>本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Participants who are currently enrolled in a...</td>\n",
+       "      <td>- Participants who are pregnant or currently i...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Participants who are continuing treatment with...</td>\n",
+       "      <td>[Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>629</th>\n",
+       "      <td>jRCT2052210099</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>screening</td>\n",
+       "      <td>Breast cancer (including suspected) (1) One of...</td>\n",
+       "      <td>(1) There is trauma with bleeding on the breas...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>The test using IGS-0001 will be performed twic...</td>\n",
+       "      <td>[Breast cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>729</th>\n",
+       "      <td>jRCT2031200057</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>&lt;Disease Characteristics&gt; 1)Patients with inop...</td>\n",
+       "      <td>1)Patients correspond to either of the followi...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>For the target tumor, the dose settled at each...</td>\n",
+       "      <td>[Breast cancer]</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>19 rows × 40 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "            JRCT ID       NCT No JapicCTI No  \\\n",
+       "32   jRCT2031240476  NCT06312176         NaN   \n",
+       "112  jRCT2031240238          NaN         NaN   \n",
+       "157  jRCT2052240059          NaN         NaN   \n",
+       "170  jRCT2031240096  NCT06380751         NaN   \n",
+       "209  jRCT2031230750  NCT06188559         NaN   \n",
+       "215  jRCT2031230723  NCT06112379         NaN   \n",
+       "224  jRCT2051230196  NCT06105632         NaN   \n",
+       "234  jRCT2031230677  NCT06206837         NaN   \n",
+       "240  jRCT2061230102  NCT06103864         NaN   \n",
+       "307  jRCT2061230074  NCT05952557         NaN   \n",
+       "351  jRCT2031230279  NCT05862285         NaN   \n",
+       "392  jRCT2031230096  NCT05774951         NaN   \n",
+       "463  jRCT2061220087  NCT05629585         NaN   \n",
+       "515  jRCT2031220276  NCT05307705         NaN   \n",
+       "555  jRCT2031220034  NCT04862663         NaN   \n",
+       "590  jRCT2031210585  NCT05123482         NaN   \n",
+       "593  jRCT2031210560  NCT05061823         NaN   \n",
+       "629  jRCT2052210099          NaN         NaN   \n",
+       "729  jRCT2031200057          NaN         NaN   \n",
+       "\n",
+       "                                                 Title  \\\n",
+       "32   ホルモン受容体陽性・ヒト上皮成長因子受容体2陰性（HR+/HER2-）の切除不能な局所進行又...   \n",
+       "112  ネクチン-4発現に関連する進行性悪性腫瘍を有する日本人患者を対象にBT8009の安全性、薬物...   \n",
+       "157  遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...   \n",
+       "170  本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...   \n",
+       "209  治療歴のある HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌の被験者を対象に，...   \n",
+       "215  未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...   \n",
+       "224  CDK4/6 阻害薬による前治療で進行したホルモン受容体陽性HER2 陰性の進行または転移乳...   \n",
+       "234  18歳以上のER陽性／HER2陰性の進行または転移乳癌患者を対象として，経口タンパク質分解誘...   \n",
+       "240  Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...   \n",
+       "307  根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...   \n",
+       "351  GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...   \n",
+       "392  根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...   \n",
+       "463  術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...   \n",
+       "515  PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...   \n",
+       "555  局所進行（切除不能）又は転移性のホルモン受容体陽性／ヒト上皮細胞成長因子受容体2 陰性乳癌を...   \n",
+       "590  進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...   \n",
+       "593  複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...   \n",
+       "629  乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...   \n",
+       "729      治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験   \n",
+       "\n",
+       "                                         TargetJ  \\\n",
+       "32                  HR+/HER2-の切除不能局所進行又は転移性乳癌の患者   \n",
+       "112                                        進行固形癌   \n",
+       "157                                          乳がん   \n",
+       "170                                         進行乳癌   \n",
+       "209               HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌   \n",
+       "215                                           乳癌   \n",
+       "224  ホルモン受容体（HR）陽性ヒト上皮増殖因子受容体2（HER2）陰性の進行または転移乳癌   \n",
+       "234       エストロゲン受容体陽性／ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌   \n",
+       "240                                           乳癌   \n",
+       "307                                    乳がん、早期乳がん   \n",
+       "351                                            癌   \n",
+       "392                                    乳がん、早期乳がん   \n",
+       "463                                           乳癌   \n",
+       "515                                          乳がん   \n",
+       "555                            局所進行（切除不能）又は転移性乳癌   \n",
+       "590                             乳癌、胆道癌、卵巣癌、子宮内膜癌   \n",
+       "593                                          固形癌   \n",
+       "629                                          乳がん   \n",
+       "729                                          乳がん   \n",
+       "\n",
+       "                                          Target  \\\n",
+       "32                  HR+/HER2-の切除不能局所進行又は転移性乳癌の患者   \n",
+       "112                                        進行固形癌   \n",
+       "157                                          乳がん   \n",
+       "170                                         進行乳癌   \n",
+       "209               HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌   \n",
+       "215                                           乳癌   \n",
+       "224  ホルモン受容体(HR)陽性ヒト上皮増殖因子受容体2(HER2)陰性の進行または転移乳癌   \n",
+       "234       エストロゲン受容体陽性/ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌   \n",
+       "240                                           乳癌   \n",
+       "307                                    乳がん、早期乳がん   \n",
+       "351                                            癌   \n",
+       "392                                    乳がん、早期乳がん   \n",
+       "463                                           乳癌   \n",
+       "515                                          乳がん   \n",
+       "555                            局所進行(切除不能)又は転移性乳癌   \n",
+       "590                             乳癌、胆道癌、卵巣癌、子宮内膜癌   \n",
+       "593                                          固形癌   \n",
+       "629                                          乳がん   \n",
+       "729                                          乳がん   \n",
+       "\n",
+       "                                         TargetEnglish  \\\n",
+       "32   HR+/HER2 unresectable locally advanced or meta...   \n",
+       "112                  Advanced solid tumor malignancies   \n",
+       "157                                      Breast cancer   \n",
+       "170                             Advanced Breast Cancer   \n",
+       "209  HER2-positive or HER2-low unresectable or meta...   \n",
+       "215                                      Breast Cancer   \n",
+       "224  HR-positive, HER2-negative Advanced or Metasta...   \n",
+       "234     ER+/HER2- advanced or metastatic breast cancer   \n",
+       "240                                      Breast Cancer   \n",
+       "307                 Breast Cancer, Early Breast Cancer   \n",
+       "351                                             Cancer   \n",
+       "392                 Breast Cancer, Early Breast Cancer   \n",
+       "463                                      Breast Cancer   \n",
+       "515                                      Breast Cancer   \n",
+       "555  Locally Advanced (Inoperable) or Metastatic Br...   \n",
+       "590  Breast Cancer, Biliary Tract Carcinoma, Ovaria...   \n",
+       "593                                             Cancer   \n",
+       "629                                      Breast cancer   \n",
+       "729                                      Breast cancer   \n",
+       "\n",
+       "                                              研究・治験の目的 試験等のフェーズ 試験の種類  ...  \\\n",
+       "32   HR+/HER2-の切除不能な局所進行又は転移性乳癌患者を対象にMK-2870の単剤及びペム...        3   NaN  ...   \n",
+       "112  第II/III相試験(NCT06225596)で使用予定のBT8009の用量について、単剤療...        1   NaN  ...   \n",
+       "157  HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...        2   NaN  ...   \n",
+       "170                                          Treatment        3   NaN  ...   \n",
+       "209                                                 治療        2   NaN  ...   \n",
+       "215  未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...        3   NaN  ...   \n",
+       "224  CDK4/6阻害薬による前治療で進行したHR陽性HER2陰性の進行または転移乳癌患者を対象に...        3   NaN  ...   \n",
+       "234  進行乳癌患者を対象として,vepdegestrantとPF-07220060を併用投与したと...      1-2   NaN  ...   \n",
+       "240  PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...        3   NaN  ...   \n",
+       "307                                          Treatment        3   NaN  ...   \n",
+       "351  本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...        3   NaN  ...   \n",
+       "392                                          Treatment        3   NaN  ...   \n",
+       "463  術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...        3   NaN  ...   \n",
+       "515  LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...        1   NaN  ...   \n",
+       "555                                          Treatment        3   NaN  ...   \n",
+       "590            進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究      1-2   NaN  ...   \n",
+       "593  本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...        3   NaN  ...   \n",
+       "629  本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...        2   NaN  ...   \n",
+       "729  TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...        1   NaN  ...   \n",
+       "\n",
+       "                purpose                                 Inclusion Criteria  \\\n",
+       "32    treatment purpose  -Has unresectable locally advanced or metastat...   \n",
+       "112   treatment purpose  1. Eastern Cooperative Oncology Group (ECOG) o...   \n",
+       "157  diagnostic purpose  1. Histologically confirmed invasive breast ca...   \n",
+       "170   treatment purpose  - Adult females, pre/peri-menopausal and/or po...   \n",
+       "209   treatment purpose  (1) Male or female, aged >=18 years at the tim...   \n",
+       "215   treatment purpose  1. Participant must be >= 18 years at the time...   \n",
+       "224   treatment purpose  * Histological confirmation of breast cancer w...   \n",
+       "234   treatment purpose  Inclusion Criteria: * Histological or cytologi...   \n",
+       "240   treatment purpose  Histologically or cytologically documented loc...   \n",
+       "307   treatment purpose  - Women and Men; 18 years or more at the time ...   \n",
+       "351   treatment purpose  - Eligible for continuing Roche IMP-based ther...   \n",
+       "392   treatment purpose  - Women and Men, greater than or equal to 18 y...   \n",
+       "463   treatment purpose  Participant must be >= 18 years at the time of...   \n",
+       "515   treatment purpose  -Have advanced breast cancer or another solid ...   \n",
+       "555   treatment purpose  Key inclusion criteria for both phases: 1. Adu...   \n",
+       "590   treatment purpose  - Age18 years or more - Relapsed/metastatic so...   \n",
+       "593   treatment purpose  - Participants who are currently enrolled in a...   \n",
+       "629           screening  Breast cancer (including suspected) (1) One of...   \n",
+       "729   treatment purpose  <Disease Characteristics> 1)Patients with inop...   \n",
+       "\n",
+       "                                    Exclusion Criteria     Age Minimum  \\\n",
+       "32   -Has breast cancer amenable to treatment with ...  18age old over   \n",
+       "112  1. Current treatment with strong inhibitors or...  18age old over   \n",
+       "157  1. History of other malignancy within the last...  20age old over   \n",
+       "170  - Participants with history of MDS/AML or with...  18age old over   \n",
+       "209  (1) Presence of brain or subdural metastases, ...  18age old over   \n",
+       "215  1. As judged by the investigator, any evidence...  18age old over   \n",
+       "224  * Any medical or psychiatric condition that ma...  18age old over   \n",
+       "234  Exclusion Criteria: * visceral crisis at risk ...  18age old over   \n",
+       "240  As judged by investigator, severe or uncontrol...  18age old over   \n",
+       "307  - Inoperable locally advanced or metastatic br...  18age old over   \n",
+       "351  - Meet any of the study treatment discontinuat...  18age old over   \n",
+       "392  - Inoperable locally advanced or metastatic br...  18age old over   \n",
+       "463  Stage IV (metastatic) TNBC. History of prior i...  18age old over   \n",
+       "515  -Medical Conditions -Colorectal cancer -Endome...  18age old over   \n",
+       "555  Key exclusion criteria for both phases: 1. His...  18age old over   \n",
+       "590  - Treatment with any of the following: 1. Nitr...  18age old over   \n",
+       "593  - Participants who are pregnant or currently i...  18age old over   \n",
+       "629  (1) There is trauma with bleeding on the breas...  20age old over   \n",
+       "729  1)Patients correspond to either of the followi...  20age old over   \n",
+       "\n",
+       "          Age Maximum  Gender Discontinuation Criteria        Keyword  \\\n",
+       "32           No limit    Both                      NaN            NaN   \n",
+       "112          No limit    Both                      NaN            NaN   \n",
+       "157          No limit  Female                      NaN            NaN   \n",
+       "170          No limit    Both                      NaN            NaN   \n",
+       "209          No limit    Both                      NaN            NaN   \n",
+       "215          No limit    Both                      NaN            NaN   \n",
+       "224          No limit    Both                      NaN            NaN   \n",
+       "234          No limit    Both                      NaN            NaN   \n",
+       "240          No limit    Both                      NaN            NaN   \n",
+       "307          No limit     NaN                      NaN            NaN   \n",
+       "351          No limit    Both                      NaN            NaN   \n",
+       "392          No limit    Both                      NaN            NaN   \n",
+       "463  130age old under    Both                      NaN            NaN   \n",
+       "515          No limit    Both                      NaN            NaN   \n",
+       "555   99age old under    Both                      NaN            NaN   \n",
+       "590          No limit    Both                      NaN            NaN   \n",
+       "593          No limit    Both                      NaN            NaN   \n",
+       "629          No limit  Female                      NaN            NaN   \n",
+       "729          No limit  Female                      NaN  Breast cancer   \n",
+       "\n",
+       "                                       Intervention(s)  \\\n",
+       "32   Arm A:MK-2870 Participants receive 4 mg/kg of ...   \n",
+       "112  In Part A, (BT8009 monotherapy) participants w...   \n",
+       "157  Omitting breast surgery after preoperative che...   \n",
+       "170  Experimental: Arm 1: saruparib (AZD5305) plus ...   \n",
+       "209  Generic Name:NA Study Treatment in dose optimi...   \n",
+       "215  - Experimental arm: Dato-DXd plus durvalumab n...   \n",
+       "224  Arm A (Experimental Arm) PF-07220060 plus Fulv...   \n",
+       "234  Drug: vepdegestrant Daily oral dosages of vepd...   \n",
+       "240  Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...   \n",
+       "307  arm A: continue with SoC ET as directed by inv...   \n",
+       "351  Ipatasertib: Ipatasertib will be administered ...   \n",
+       "392  arm A: continue with SoC ET as directed by inv...   \n",
+       "463  Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...   \n",
+       "515  -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...   \n",
+       "555  Capivasertib: PO BD 4 days on /3 days off per ...   \n",
+       "590  Sub-study1 AZD8205 Monotherapy AZD8205 is an a...   \n",
+       "593  Participants who are continuing treatment with...   \n",
+       "629  The test using IGS-0001 will be performed twic...   \n",
+       "729  For the target tumor, the dose settled at each...   \n",
+       "\n",
+       "                                            TargetWord  \n",
+       "32   [HR+/HER2 unresectable locally advanced, metas...  \n",
+       "112                 [Advanced solid tum, malignancies]  \n",
+       "157                                    [Breast cancer]  \n",
+       "170                           [Advanced Breast Cancer]  \n",
+       "209  [HER2-positive, HER2-low unresectable, metasta...  \n",
+       "215                                    [Breast Cancer]  \n",
+       "224  [HR-positive, HER2-negative Advanced, Metastat...  \n",
+       "234     [ER+/HER2- advanced, metastatic breast cancer]  \n",
+       "240                                    [Breast Cancer]  \n",
+       "307               [Breast Cancer, Early Breast Cancer]  \n",
+       "351                                           [Cancer]  \n",
+       "392               [Breast Cancer, Early Breast Cancer]  \n",
+       "463                                    [Breast Cancer]  \n",
+       "515                                    [Breast Cancer]  \n",
+       "555  [Locally Advanced (Inoperable), Metastatic Bre...  \n",
+       "590  [Breast Cancer, Biliary Tract Carcinoma, Ovari...  \n",
+       "593                                           [Cancer]  \n",
+       "629                                    [Breast cancer]  \n",
+       "729                                    [Breast cancer]  \n",
+       "\n",
+       "[19 rows x 40 columns]"
+      ]
+     },
+     "execution_count": 53,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "# ターゲットリスト全体を処理\n",
+    "matched_indices = []\n",
+    "target_vecs_list = []\n",
+    "cosine_scores_list = []\n",
+    "for idx, target_words in enumerate(basedf['TargetWord']):\n",
+    "    # ターゲット内の各単語をベクトル化\n",
+    "    target_vecs = model.encode(target_words, convert_to_tensor=True)\n",
+    "    # コサイン類似度を計算\n",
+    "    cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n",
+    "    target_vecs_list.append(target_vecs)\n",
+    "    cosine_scores_list.append(cosine_scores)\n",
+    "    # 閾値を超えるか確認\n",
+    "    if (cosine_scores >= threshold).any():  # いずれかが閾値を超えている場合\n",
+    "        matched_indices.append(idx)\n",
+    "\n",
+    "# 抽出\n",
+    "matched_df = basedf.iloc[matched_indices]\n",
+    "matched_df"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 42,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# 全データのターゲット列をベクトル化\n",
+    "target_list = basedf['TargetEnglish'].tolist()\n",
+    "target_vecs = model.encode(target_list, convert_to_tensor=True)\n",
+    "# コサイン類似度を計算\n",
+    "cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 43,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>JRCT ID</th>\n",
+       "      <th>NCT No</th>\n",
+       "      <th>JapicCTI No</th>\n",
+       "      <th>Title</th>\n",
+       "      <th>TargetJ</th>\n",
+       "      <th>Target</th>\n",
+       "      <th>TargetEnglish</th>\n",
+       "      <th>研究・治験の目的</th>\n",
+       "      <th>試験等のフェーズ</th>\n",
+       "      <th>試験の種類</th>\n",
+       "      <th>...</th>\n",
+       "      <th>purpose</th>\n",
+       "      <th>Inclusion Criteria</th>\n",
+       "      <th>Exclusion Criteria</th>\n",
+       "      <th>Age Minimum</th>\n",
+       "      <th>Age Maximum</th>\n",
+       "      <th>Gender</th>\n",
+       "      <th>Discontinuation Criteria</th>\n",
+       "      <th>Keyword</th>\n",
+       "      <th>Intervention(s)</th>\n",
+       "      <th>TargetWord</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>157</th>\n",
+       "      <td>jRCT2052240059</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>diagnostic purpose</td>\n",
+       "      <td>1. Histologically confirmed invasive breast ca...</td>\n",
+       "      <td>1. History of other malignancy within the last...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Omitting breast surgery after preoperative che...</td>\n",
+       "      <td>[Breast cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>170</th>\n",
+       "      <td>jRCT2031240096</td>\n",
+       "      <td>NCT06380751</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...</td>\n",
+       "      <td>進行乳癌</td>\n",
+       "      <td>進行乳癌</td>\n",
+       "      <td>Advanced Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Adult females, pre/peri-menopausal and/or po...</td>\n",
+       "      <td>- Participants with history of MDS/AML or with...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Experimental: Arm 1: saruparib (AZD5305) plus ...</td>\n",
+       "      <td>[Advanced Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>215</th>\n",
+       "      <td>jRCT2031230723</td>\n",
+       "      <td>NCT06112379</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>���治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Participant must be &gt;= 18 years at the time...</td>\n",
+       "      <td>1. As judged by the investigator, any evidence...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>- Experimental arm: Dato-DXd plus durvalumab n...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>240</th>\n",
+       "      <td>jRCT2061230102</td>\n",
+       "      <td>NCT06103864</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Histologically or cytologically documented loc...</td>\n",
+       "      <td>As judged by investigator, severe or uncontrol...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>307</th>\n",
+       "      <td>jRCT2061230074</td>\n",
+       "      <td>NCT05952557</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>Breast Cancer, Early Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Women and Men; 18 years or more at the time ...</td>\n",
+       "      <td>- Inoperable locally advanced or metastatic br...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>arm A: continue with SoC ET as directed by inv...</td>\n",
+       "      <td>[Breast Cancer, Early Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>351</th>\n",
+       "      <td>jRCT2031230279</td>\n",
+       "      <td>NCT05862285</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...</td>\n",
+       "      <td>癌</td>\n",
+       "      <td>癌</td>\n",
+       "      <td>Cancer</td>\n",
+       "      <td>本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Eligible for continuing Roche IMP-based ther...</td>\n",
+       "      <td>- Meet any of the study treatment discontinuat...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Ipatasertib: Ipatasertib will be administered ...</td>\n",
+       "      <td>[Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>392</th>\n",
+       "      <td>jRCT2031230096</td>\n",
+       "      <td>NCT05774951</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>Breast Cancer, Early Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Women and Men, greater than or equal to 18 y...</td>\n",
+       "      <td>- Inoperable locally advanced or metastatic br...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>arm A: continue with SoC ET as directed by inv...</td>\n",
+       "      <td>[Breast Cancer, Early Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>463</th>\n",
+       "      <td>jRCT2061220087</td>\n",
+       "      <td>NCT05629585</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Participant must be &gt;= 18 years at the time of...</td>\n",
+       "      <td>Stage IV (metastatic) TNBC. History of prior i...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>130age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>515</th>\n",
+       "      <td>jRCT2031220276</td>\n",
+       "      <td>NCT05307705</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Have advanced breast cancer or another solid ...</td>\n",
+       "      <td>-Medical Conditions -Colorectal cancer -Endome...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>593</th>\n",
+       "      <td>jRCT2031210560</td>\n",
+       "      <td>NCT05061823</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...</td>\n",
+       "      <td>固形癌</td>\n",
+       "      <td>固形癌</td>\n",
+       "      <td>Cancer</td>\n",
+       "      <td>本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Participants who are currently enrolled in a...</td>\n",
+       "      <td>- Participants who are pregnant or currently i...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Participants who are continuing treatment with...</td>\n",
+       "      <td>[Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>629</th>\n",
+       "      <td>jRCT2052210099</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>screening</td>\n",
+       "      <td>Breast cancer (including suspected) (1) One of...</td>\n",
+       "      <td>(1) There is trauma with bleeding on the breas...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>The test using IGS-0001 will be performed twic...</td>\n",
+       "      <td>[Breast cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>729</th>\n",
+       "      <td>jRCT2031200057</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>&lt;Disease Characteristics&gt; 1)Patients with inop...</td>\n",
+       "      <td>1)Patients correspond to either of the followi...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>For the target tumor, the dose settled at each...</td>\n",
+       "      <td>[Breast cancer]</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>12 rows × 40 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "            JRCT ID       NCT No JapicCTI No  \\\n",
+       "157  jRCT2052240059          NaN         NaN   \n",
+       "170  jRCT2031240096  NCT06380751         NaN   \n",
+       "215  jRCT2031230723  NCT06112379         NaN   \n",
+       "240  jRCT2061230102  NCT06103864         NaN   \n",
+       "307  jRCT2061230074  NCT05952557         NaN   \n",
+       "351  jRCT2031230279  NCT05862285         NaN   \n",
+       "392  jRCT2031230096  NCT05774951         NaN   \n",
+       "463  jRCT2061220087  NCT05629585         NaN   \n",
+       "515  jRCT2031220276  NCT05307705         NaN   \n",
+       "593  jRCT2031210560  NCT05061823         NaN   \n",
+       "629  jRCT2052210099          NaN         NaN   \n",
+       "729  jRCT2031200057          NaN         NaN   \n",
+       "\n",
+       "                                                 Title    TargetJ     Target  \\\n",
+       "157  遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...        乳がん        乳がん   \n",
+       "170  本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...       進行乳癌       進行乳癌   \n",
+       "215  未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...         乳癌         乳癌   \n",
+       "240  Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...         乳癌         乳癌   \n",
+       "307  根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...  乳がん、早期乳がん  乳がん、早期乳がん   \n",
+       "351  GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...          癌          癌   \n",
+       "392  根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...  乳がん、早期乳がん  乳がん、早期乳がん   \n",
+       "463  術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...         乳癌         乳癌   \n",
+       "515  PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...        乳がん        乳がん   \n",
+       "593  複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...        固形癌        固形癌   \n",
+       "629  乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...        乳がん        乳がん   \n",
+       "729      治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験        乳がん        乳がん   \n",
+       "\n",
+       "                          TargetEnglish  \\\n",
+       "157                       Breast cancer   \n",
+       "170              Advanced Breast Cancer   \n",
+       "215                       Breast Cancer   \n",
+       "240                       Breast Cancer   \n",
+       "307  Breast Cancer, Early Breast Cancer   \n",
+       "351                              Cancer   \n",
+       "392  Breast Cancer, Early Breast Cancer   \n",
+       "463                       Breast Cancer   \n",
+       "515                       Breast Cancer   \n",
+       "593                              Cancer   \n",
+       "629                       Breast cancer   \n",
+       "729                       Breast cancer   \n",
+       "\n",
+       "                                              研究・治験の目的 試験等のフェーズ 試験の種類  ...  \\\n",
+       "157  HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...        2   NaN  ...   \n",
+       "170                                          Treatment        3   NaN  ...   \n",
+       "215  未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...        3   NaN  ...   \n",
+       "240  PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...        3   NaN  ...   \n",
+       "307                                          Treatment        3   NaN  ...   \n",
+       "351  本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...        3   NaN  ...   \n",
+       "392                                          Treatment        3   NaN  ...   \n",
+       "463  術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...        3   NaN  ...   \n",
+       "515  LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...        1   NaN  ...   \n",
+       "593  本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...        3   NaN  ...   \n",
+       "629  本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...        2   NaN  ...   \n",
+       "729  TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...        1   NaN  ...   \n",
+       "\n",
+       "                purpose                                 Inclusion Criteria  \\\n",
+       "157  diagnostic purpose  1. Histologically confirmed invasive breast ca...   \n",
+       "170   treatment purpose  - Adult females, pre/peri-menopausal and/or po...   \n",
+       "215   treatment purpose  1. Participant must be >= 18 years at the time...   \n",
+       "240   treatment purpose  Histologically or cytologically documented loc...   \n",
+       "307   treatment purpose  - Women and Men; 18 years or more at the time ...   \n",
+       "351   treatment purpose  - Eligible for continuing Roche IMP-based ther...   \n",
+       "392   treatment purpose  - Women and Men, greater than or equal to 18 y...   \n",
+       "463   treatment purpose  Participant must be >= 18 years at the time of...   \n",
+       "515   treatment purpose  -Have advanced breast cancer or another solid ...   \n",
+       "593   treatment purpose  - Participants who are currently enrolled in a...   \n",
+       "629           screening  Breast cancer (including suspected) (1) One of...   \n",
+       "729   treatment purpose  <Disease Characteristics> 1)Patients with inop...   \n",
+       "\n",
+       "                                    Exclusion Criteria     Age Minimum  \\\n",
+       "157  1. History of other malignancy within the last...  20age old over   \n",
+       "170  - Participants with history of MDS/AML or with...  18age old over   \n",
+       "215  1. As judged by the investigator, any evidence...  18age old over   \n",
+       "240  As judged by investigator, severe or uncontrol...  18age old over   \n",
+       "307  - Inoperable locally advanced or metastatic br...  18age old over   \n",
+       "351  - Meet any of the study treatment discontinuat...  18age old over   \n",
+       "392  - Inoperable locally advanced or metastatic br...  18age old over   \n",
+       "463  Stage IV (metastatic) TNBC. History of prior i...  18age old over   \n",
+       "515  -Medical Conditions -Colorectal cancer -Endome...  18age old over   \n",
+       "593  - Participants who are pregnant or currently i...  18age old over   \n",
+       "629  (1) There is trauma with bleeding on the breas...  20age old over   \n",
+       "729  1)Patients correspond to either of the followi...  20age old over   \n",
+       "\n",
+       "          Age Maximum  Gender Discontinuation Criteria        Keyword  \\\n",
+       "157          No limit  Female                      NaN            NaN   \n",
+       "170          No limit    Both                      NaN            NaN   \n",
+       "215          No limit    Both                      NaN            NaN   \n",
+       "240          No limit    Both                      NaN            NaN   \n",
+       "307          No limit     NaN                      NaN            NaN   \n",
+       "351          No limit    Both                      NaN            NaN   \n",
+       "392          No limit    Both                      NaN            NaN   \n",
+       "463  130age old under    Both                      NaN            NaN   \n",
+       "515          No limit    Both                      NaN            NaN   \n",
+       "593          No limit    Both                      NaN            NaN   \n",
+       "629          No limit  Female                      NaN            NaN   \n",
+       "729          No limit  Female                      NaN  Breast cancer   \n",
+       "\n",
+       "                                       Intervention(s)  \\\n",
+       "157  Omitting breast surgery after preoperative che...   \n",
+       "170  Experimental: Arm 1: saruparib (AZD5305) plus ...   \n",
+       "215  - Experimental arm: Dato-DXd plus durvalumab n...   \n",
+       "240  Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...   \n",
+       "307  arm A: continue with SoC ET as directed by inv...   \n",
+       "351  Ipatasertib: Ipatasertib will be administered ...   \n",
+       "392  arm A: continue with SoC ET as directed by inv...   \n",
+       "463  Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...   \n",
+       "515  -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...   \n",
+       "593  Participants who are continuing treatment with...   \n",
+       "629  The test using IGS-0001 will be performed twic...   \n",
+       "729  For the target tumor, the dose settled at each...   \n",
+       "\n",
+       "                               TargetWord  \n",
+       "157                       [Breast cancer]  \n",
+       "170              [Advanced Breast Cancer]  \n",
+       "215                       [Breast Cancer]  \n",
+       "240                       [Breast Cancer]  \n",
+       "307  [Breast Cancer, Early Breast Cancer]  \n",
+       "351                              [Cancer]  \n",
+       "392  [Breast Cancer, Early Breast Cancer]  \n",
+       "463                       [Breast Cancer]  \n",
+       "515                       [Breast Cancer]  \n",
+       "593                              [Cancer]  \n",
+       "629                       [Breast cancer]  \n",
+       "729                       [Breast cancer]  \n",
+       "\n",
+       "[12 rows x 40 columns]"
+      ]
+     },
+     "execution_count": 43,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "matched_indices_d = (cosine_scores >= threshold).nonzero().tolist()\n",
+    "# 入れ子リストをフラットなリストに変換\n",
+    "flat_indices_d = [idx[0] for idx in matched_indices_d]\n",
+    "\n",
+    "# 抽出\n",
+    "matched_df_d = basedf.iloc[flat_indices_d]\n",
+    "matched_df_d\n"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": []
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": [
+    "\n"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": []
+  }
+ ],
+ "metadata": {
+  "kernelspec": {
+   "display_name": "gradio",
+   "language": "python",
+   "name": "python3"
+  },
+  "language_info": {
+   "codemirror_mode": {
+    "name": "ipython",
+    "version": 3
+   },
+   "file_extension": ".py",
+   "mimetype": "text/x-python",
+   "name": "python",
+   "nbconvert_exporter": "python",
+   "pygments_lexer": "ipython3",
+   "version": "3.12.3"
+  }
+ },
+ "nbformat": 4,
+ "nbformat_minor": 2
+}